HealthEquity, Inc.
NASDAQ:HQY · NASDAQ Global Select
-$0.54 today
Vol 1.20M · Avg 0.98M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:HQY · Revenue to Net Income
Key Ratios
Analysis
$1.3B of revenue converted into $230.7M of net income for the selected period. Gross margin is 72.5% and net margin is 17.2%, showing how much revenue survives after costs and taxes. EPS is $2.67, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B +9.5% | $1.2B +20.0% | $999.6M +16.0% | $861.7M +13.9% | $756.6M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $400.3M -21.1% | $507.2M +8.0% | $469.7M +0.7% | $466.2M +12.2% | $415.6M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $913.1M +31.8% | $692.6M +30.7% | $529.9M +34.0% | $395.5M +16.0% | $340.9M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 69.5% +11.8pp | 57.7% +4.7pp | 53.0% +7.1pp | 45.9% +0.8pp | 45.1% | 45.5% | 9.8% | 28.9% |
| Research & Development | $262.5M +9.6% | $239.5M +9.5% | $218.8M +13.2% | $193.4M +22.9% | $157.4M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $328.1M +47.2% | $223.0M +21.9% | $182.9M +11.2% | $164.5M +15.0% | $143.0M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $590.7M +27.7% | $462.5M +15.1% | $401.7M +12.3% | $357.9M +19.1% | $300.3M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $154.7M -4.8% | $162.5M +6.1% | $153.1M -5.0% | $161.2M +17.5% | $137.2M | $1.2B | $374.2M | $1.2B |
| EBITDA | $489.2M +44.9% | $337.5M +19.5% | $282.4M +64.6% | $171.5M +66.6% | $103.0M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 37.2% +9.1pp | 28.1% -0.1pp | 28.3% +8.3pp | 19.9% +6.3pp | 13.6% | 10.0% | 5.6% | 46.3% |
| Operating Income | $322.5M +40.2% | $230.1M +79.6% | $128.1M +240.3% | $37.7M -7.2% | $40.6M | $10.6B | $12.3B | $14.0B |
| Operating Margin | 24.6% +5.4pp | 19.2% +6.4pp | 12.8% +8.4pp | 4.4% -1.0pp | 5.4% | 18.7% | 16.6% | 24.1% |
| Interest Income | $12.1M -13.0% | $13.9M +14.6% | $12.1M +588.5% | $1.8M +17.5% | $1.5M | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $57.1M -5.8% | $60.6M +9.3% | $55.5M +14.5% | $48.4M +32.4% | $36.6M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$45.0M +60.5% | -$114.0M -114.8% | -$53.1M +29.9% | -$75.7M +29.4% | -$107.3M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | $277.4M +139.1% | $116.0M +54.6% | $75.0M +297.0% | -$38.1M +42.9% | -$66.7M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | 21.1% +11.5pp | 9.7% +2.2pp | 7.5% +11.9pp | -4.4% +4.4pp | -8.8% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $62.2M +221.9% | $19.3M +0.0% | $19.3M +261.7% | -$12.0M +46.8% | -$22.5M | $666.8M | $1.3B | -$1.6B |
| Net Income | $215.2M +122.5% | $96.7M +73.6% | $55.7M +313.1% | -$26.1M +41.0% | -$44.3M | $5.0B | $4.9B | $4.8B |
| Net Margin | 16.4% +8.3pp | 8.1% +2.5pp | 5.6% +8.6pp | -3.0% +2.8pp | -5.9% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $3 +125.2% | $1 +70.8% | $1 +309.7% | -$0 +41.5% | -$1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $2 +125.7% | $1 +70.3% | $1 +306.5% | -$0 +41.5% | -$1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $86.1M -0.8% | $86.9M +1.5% | $85.6M +1.3% | $84.4M +1.6% | $83.1M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $87.5M -1.5% | $88.8M +2.2% | $87.0M +3.0% | $84.4M +1.6% | $83.1M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.67B
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.88B
Penumbra, Inc.
NYSE:PEN
$12.44B
Globus Medical, Inc.
NYSE:GMED
$10.25B
Molina Healthcare, Inc.
NYSE:MOH
$10.23B
Henry Schein, Inc.
NASDAQ:HSIC
$9.06B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.84B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.70B
Hims & Hers Health, Inc.
NYSE:HIMS
$7.34B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HQY generate?
HealthEquity, Inc. (HQY) reported $1.31B of revenue in fiscal 2026.
Is HQY profitable?
HealthEquity, Inc. (HQY) reported $215.20M of net income, with a net margin of 16.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.